biosimilaradj.n.

Brit.

/ˌbʌɪəʊˈsɪm(ᵻ)lə/, U.S.

/ˌbaɪoʊˈsɪm(ə)lər/

Origin: Formed within English, by compounding. Etymons: bio- comb. form, similar adj.

Etymology: < bio- comb. form + similar adj.

Medicine.

A. adj.

Of a biopharmaceutical, esp. one produced by recombinant DNA technology: designed to have active properties similar to those of a previously licensed biopharmaceutical. Cf. biogeneric adj.

ΘΚΠ

the world > health and disease > healing > medicines or physic > [adjective] > other qualities of medicines

lighteOE

emphractic1659

concentrant1721

potentized1851

antiperiodic1861

weak1899

stathmokinetic1939

bioavailable1973

biosimilar2002

2002 European Drug Rep. 4 Nov. 2/2 Biosimilar products—those having the same physico-chemical and biological properties and pharmaceutical form as the brand drug.

2009 H. Schellekens in S. G. Elliott et al. Erythropoietins, Erythropoietic Factors, & Erythropoiesis (ed. 2) 111 Alpheon, a biosimilar version of Roferon-A (IFN alfa-2a), was rejected by the EMEA.

2011 N.Y. Times (Nexis) 20 Dec. b6 Amgen has plans for other biosimilar drugs.

B. n.

A biosimilar drug. Cf. biogeneric n.

ΚΠ

2003 Pharma Marketletter (Nexis) 6 Oct. To be approved, ‘biosimilars’ must undergo a re-clinical testing and clinical trials procedure which is different from..generic versions of chemical drugs.

2013 M. Osmane Rift-lines European Regulatory Framework for Biosimilars vi. 210 The biosimilar..must show independent safety for patients by clinical trials.

This is a new entry (OED Third Edition, June 2014; most recently modified version published online December 2021).

单词	biosimilar
释义	biosimilaradj.n. Brit. /ˌbʌɪəʊˈsɪm(ᵻ)lə/, U.S. /ˌbaɪoʊˈsɪm(ə)lər/ Origin: Formed within English, by compounding. Etymons: bio- comb. form, similar adj. Etymology: < bio- comb. form + similar adj. Medicine. A. adj. Of a biopharmaceutical, esp. one produced by recombinant DNA technology: designed to have active properties similar to those of a previously licensed biopharmaceutical. Cf. biogeneric adj. ΘΚΠ the world > health and disease > healing > medicines or physic > [adjective] > other qualities of medicines lighteOE emphractic1659 concentrant1721 potentized1851 antiperiodic1861 weak1899 stathmokinetic1939 bioavailable1973 biosimilar2002 2002 European Drug Rep. 4 Nov. 2/2 Biosimilar products—those having the same physico-chemical and biological properties and pharmaceutical form as the brand drug. 2009 H. Schellekens in S. G. Elliott et al. Erythropoietins, Erythropoietic Factors, & Erythropoiesis (ed. 2) 111 Alpheon, a biosimilar version of Roferon-A (IFN alfa-2a), was rejected by the EMEA. 2011 N.Y. Times (Nexis) 20 Dec. b6 Amgen has plans for other biosimilar drugs. B. n. A biosimilar drug. Cf. biogeneric n. ΚΠ 2003 Pharma Marketletter (Nexis) 6 Oct. To be approved, ‘biosimilars’ must undergo a re-clinical testing and clinical trials procedure which is different from..generic versions of chemical drugs. 2013 M. Osmane Rift-lines European Regulatory Framework for Biosimilars vi. 210 The biosimilar..must show independent safety for patients by clinical trials. This is a new entry (OED Third Edition, June 2014; most recently modified version published online December 2021). < adj.n.2002
随便看	joinedup government joinedup handwriting joinedup thinking joinedup writing joiner joiner's plane joiner's work joiner-work joineries joinering joiners joinerwork joinery joinhand joining joining of battle joining up joining-hand joining-place joining-work joininghand joiningly joiningplace joinings joiningwork